Fiore M, Forli S, Manetti F. Targeting mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK2, MK2): Medicinal chemistry efforts to lead small molecule inhibitors to clinical trials. J Med Chem 2016; 59(8): 3609-34.
Xing L. Clinical candidates of small molecule p38 MAPK inhibitors for inflammatory diseases. MAP Kinase 2015; 4: 5508-14.
Moens U, Kostenko S, Sveinbjornsson B. The role of mitogen activated protein kinase-activated protein kinases (MAPKAPKs) in inflammation. Genes 2013; 4: 101-33.
Gaestel M. What goes up must come down: Molecular basis of MAPKAP kinase 2/3-dependent regulation of the inflammatory response and its inhibition. Biol Chem 2013; 394: 1301-15.
Edmunds JJ, Talanian RV. MAPKAP kinase 2 as a target for anti-inflammatory drug discovery. London: The Royal Society of Chemistry 2012.
Ehlting C, Ronkina N, Bohmer O, et al. Distinct Functions of the Mitogen-activated Protein Kinase-activated Protein (MAPKAP) Kinases MK2 and MK3. J Biol Chem 2011; 286(27): 24113-24.
Hammaker D, Firestein GS. “Go upstream, young man”: Lessons learned from the p38 saga. Ann Rheum Dis 2010; 69(S1): i77-82.
Goldstein DM, Kuglstatter A, Lou Y, Soth MJ. Selective p38alpha inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J Med Chem 2010; 53: 2345-53.
Karcher SC, Laufer SA. Successful structure-based design of recent p38 MAP kinase inhibitors. Curr Top Med Chem 2009; 9: 655-76.
Genovese MC. Inhibition of p38: Has the fat lady sung? Arthritis Rheumatol 2009; 60: 317-20.
Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38(MAPK): Stress responses from molecular mechanisms to therapeutics. Trends Mol Med 2009; 15: 369-79.
Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009; 21: 317-24.
Peifer C, Wagner G, Laufer S. New approaches to the treatment of infl ammatory disorders small molecule inhibitors of p38MAP kinase. Curr Top Med Chem 2006; 6(2): 113-9.
Lee MR, Dominguez C. MAP Kinase p38 Inhibitors: Clinical results and an intimate look at their interactions with p38 protein. Curr Med Chem 2005; 12: 2979-94.
Jr JH, Leftheri K. Small molecule p38 inhibitors: Novel structural features and advances from 2002–2005. Curr Top Med Chem 2005; 5: 967-85.
Diller DJ, Lin TH, Metzger A. The discovery of novel chemotypes of p38 kinase inhibitors. Curr Top Med Chem 2005; 5: 953-65.
Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004; 4(4): 372-7.
Chopra P, Kanoje V, Semwal A, Ray A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs 2008; 17(10): 1411-25.
Dominguez C, Powers DA, Tamayo N. p38 MAP kinase inhibitors: Many are made, but few are chosen. Curr Opin Drug Discov 2005; 8: 421-30.
Dambach DM. Potential adverse effects associated with inhibition of p38 α/β MAPkinases. Curr Top Med Chem 2005; 5(10): 929-39.
Allen M, Svensson L, Roach M, Hambor J, McNeish J, Gabel CA. Deficiency of the stress kinase p38 results in embryonic lethality: characterization of the kinase dependence of stress responses of enzyme defi cient embryonic stem cells. J Exp Med 2000; 191: 859-70.
Lee JC, Kassis S, Kumar S, Badger A, Adams JL. p38 mitogen-activated protein kinase inhibitors-mechanisms and therapeutic potentials. Pharmacol Ther 1999; 82(2-3): 389-97.
Clement SL, Scheckel C, Stoecklin G, Andersen JL. Phosphorylation of tristetraprolin by MK2 impairs AU-rich element mRNA decay by preventing deadenylase recruitment. Mol Cell Biol 2011; 31(2): 256-66.
Fyhrquist N, Matikainen S, Lauerma A. MK2 signaling: Lessons on tissue specificity in modulation of inflammation. J Invest Dermatol 2010; 130: 342-4.
Duraisamy S, Bajpai M, Bughani U, Dastidar SG, Ray A, Chopra P. MK2: A novel molecular target for anti-inflammatory therapy. Expert Opin Ther Targets 2008; 12(8): 921-36.
Vandendriessche B, Goethals A, Simats A, Hamme EV, Brouckaert P, Cauwels A. MAPK-activated protein kinase 2-deficiency causes hyperacute tumor necrosis factor-induced inflammatory shock. BMC Physiol 2014; 14(1): 1-10.
Ronkina N, Menon MB, Schwermann J, et al. MAPKAP kinases MK2 and MK3 in inflammation: Complex regulation of TNF biosynthesis via expression and phosphorylation of tristetraprolin. Biochem Pharmacol 2010; 80: 1915-20.
Hegen M, Gaestel M, Nickerson-Nutter CL, Lin LL, Telliez JB. MAPKAP kinase 2-deficient mice are resistant to collagen-induced arthritis. J Immunol 2006; 177: 1913-7.
Lehner MD, Schwoebel F, Kotlyarov A. Mitogen-activated protein kinase-activated protein kinase 2-deficient mice show increased susceptibility to Listeria monocytogenes infection. J Immunol 2002; 168(9): 4667-73.
Kotlyarov A, Gaestel M. Is MK2 (mitogen-activated protein kinase-activated protein kinase 2) the key for understanding post-transcriptional regulation of gene expression? Biochem Soc Trans 2002; 30(6): 959-63.
Kotlyarov A, Neininger A, Schubert C, et al. MAPKAP kinase 2 is essential for LPS-induced TNF-alpha biosynthesis. Nat Cell Biol 1999; 1: 94-7.
Singh R, Diwan M, Dastidar S, Najmi A. Differential effect of p38 and MK2 kinase inhibitors on the inflammatory and toxicity biomarkers in vitro. Hum Exp Toxicol 2018; 37(5): 521-31.
Singh RK, Najmi AK, Dastidar SG. Biological functions and role of mitogen-activated protein kinase activated protein kinase 2 (MK2) in inflammatory diseases. Pharmacol Rep 2017; 69: 746-56.
Khorasanizadeh M, Eskian M, Gelfand EW, Rezaei N. Mitogen-activated protein kinases as therapeutic targets for asthma. Pharmacol Ther 2017; 174: 112-26.
Wu T, Shi J-X, Geng S, Zhou W, Shi Y, Su X. The MK2/HuR signaling pathway regulates TNF-α-induced ICAM-1 expression by promoting the stabilization of ICAM-1 mRNA. BMC Pulm Med 2016; 16: 84-94.
Qian F, Deng J, Wang G, Ye RD, Christman JW. Pivotal Role of mitogen-activated protein kinase-activated protein kinase 2 in inflammatory pulmonary diseases. Curr Protein Pept Sci 2016; 17(4): 332-42.
Chupp G, Yan X, Nezgovorova V, et al. MAPKAP kinase 2(MK2) expression is associated with severe asthma. Eur Respir J 2016; 48(60): PA4649.
Vittal R, Fisher A, Gu H, et al. Peptide-Mediated inhibition of mitogen-activated protein kinase–activated protein kinase–2 ameliorates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2013; 49(1): 47-57.
Loomis-King H, Flaherty KR, Moore BB. Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. Curr Opin Pharmacol 2013; 13(3): 377-85.
Su X, Ao L, Zou N, et al. Post-transcriptional regulation of TNF-induced expression of ICAM-1 and IL-8 in human lung microvascular endothelial cells: An obligatory role for the p38 MAPK-MK2 pathway dissociated with HSP27. BBA-Mol Cell Res 2008; 1783(9): 1623-31.
Greenberg AK, Basu S, Hu J, et al. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol 2002; 26(5): 558-64.
Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008; 359(13): 1367-80.
Jackson EL, Olive KP, Tuveson DA, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005; 65(22): 10280-8.
Damarla M, Hasan E, Boueiz A, et al. Mitogen activated protein kinase activated protein kinase 2 regulates actin polymerization and vascular leak in ventilator associated lung injury. PLoS One 2009; 4(2): e4600.
Damarla M, Parniani AR, Johnston L, et al. Mitogen-activated protein kinase-activated protein kinase 2 mediates apoptosis during lung vascular permeability by regulating movement of cleaved caspase 3. Am J Respir Cell Mol Biol 2014; 50(5): 932-41.
Kayyali US, Pennella CM, Trujillo C, Villa O, Gaestel M, Hassoun PM. Cytoskeletal changes in hypoxic pulmonary endothelial cells are dependent on MAPK-activated protein kinase MK2. J Biol Chem 2002; 277(45): 42596-602.
Meng W, Swenson LL, Fitzgibbon MJ, et al. Structure of Mitogen-Activated Protein Kinase-Activated Protein (MAPKAP) kinase 2 suggests a bifunctional switch that couples kinase activation with nuclear export. J Biol Chem 2002; 277: 37401-5.
Neininger A, Thielemann H, Gaestel M. FRET-based detection of different conformations of MK2. EMBO Rep 2001; 2: 703-8.
Ben-Levy R, Hooper S, Wilson R, Paterson HF, Marshall CJ. Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Curr Biol 1998; 8: 1049-57.
Ben-Levy R, Leighton IA, Doza YN, et al. Identification of novel phosphorylation sites required for activation of MAPKAP kinase-2. EMBO J 1995; 14: 5920-30.
White A, Pargellis CA, Studts JM, Werneburg BG, Farmer BT. Molecular basis of MAPK-activated protein kinase 2: p38 assembly. Proc Natl Acad Sci USA 2007; 104: 6353-8.
Natesan S, Subramaniam R, Bergeron C, Balaz S. Binding affinity prediction for ligands and receptors forming tautomers and ionization species: inhibition of mitogen-activated protein kinase activated protein kinase 2 (MK2). J Med Chem 2012; 55: 2035-47.
Underwood KW, Parris KD, Federico E, et al. Catalytically active MAPKAP kinase 2 structures in complex with staurosporine and ADP reveal differences with the autoinhibited enzyme. Structure 2003; 11: 627-36.
Kotlyarov A, Yannoni Y, Fritz S, et al. Distinct cellular functions of MK2. Mol Cell Biol 2002; 22(13): 4827-35.
Ronkina N, Kotlyarov A, Gaestel M. MK2 and MK3-a pair of isoenzymes? Front Biosci 2008; 13: 5511-21.
Cargnello M, Roux PP. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 2011; 75: 50-83.
Gaestel M. MAPKAP kinases-MKs-two’s company, three’s a crowd. Nat Rev Mol Cell Biol 2006; 7: 120-30.
Stoecklin G, Stubbs T, Kedersha N, et al. MK2-induced tristetraprolin:14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J 2004; 23: 1313-24.
Arthur JSC, Ley SC. Mitogen-activated protein kinases in innate immunity. Nat Rev Immunol 2013; 13: 679-92.
Blink BVd, Juffermans NP, Hove Tt, et al. P38 Mitogen-activated
protein kinase inhibition increases cytokine release by macrophages
in vitro and during infection in vivo.. J Immunol 2001; 166:
Branger J. Anti-Inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. J Immunol 2002; 168: 4070-7.
Cheung PC, Campbell DG, Nebreda AR, Cohen P. Feedback control of the protein kinase TAK1 by SAPK2a/p38α. EMBO J 2003; 22: 5793-805.
Dobreva ZG, Miteva LD, Stanilova SA. The inhibition of JNK and p38 MAPKs downregulates IL-10 and differentially affects c-Jun gene expression in human monocytes. Immunopharmacol Immunotoxicol 2009; 31(2): 195-201.
Pettus LH, Wurz RP. Small-molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: Novel structures and developments during 2006-2008. Curr Top Med Chem 2008; 8: 1452-67.
Regan J, Breitfelder S, Cirillo P, et al. Pyrazole urea-based inhibitors of p38 MAP kinase: From lead compound to clinical candidate. J Med Chem 2002; 45: 2994-3008.
Ryoo S, Choi J, Kim J, et al. BIRB 796 has distinctive anti-inflammatory effects on different cell types. Immune Netw 2013; 13(6): 283-8.
Wilson KP, McCaffrey PG, Hsiao K, et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 1997; 4: 423-31.
Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 2007; 28(6): 286-95.
Hale KK, Trollinger D, Rihanek M, Manthey CL. Differential expression and activation of p38 mitogen-activated protein kinase alpha, beta, gamma, and delta in inflammatory cell lineages. J Immunol 1999; 162: 4246-52.
Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, Adams JL. Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacol 2000; 47: 185-201.
Natarajan SR, Doherty JB. P38 MAP kinase inhibitors: Evolution of imidazole based and pyrido-pyrimidin-2-one lead classes. Curr Top Med Chem 2005; 5: 987-1003.
Pargellis C, Regan J. Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr Opin Investig Drugs 2003; 4(5): 566-71.
Goldstein DM, Gabriel T. Pathway to the clinic: Inhibition of P38 MAP Kinase. A review of ten chemotypes selected for development. Curr Top Med Chem 2005; 5: 1017-29.
Marber MS, Molkentin JD, Force T. Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in point. Drug Discov Today Dis Mech 2010; 7(2): e123-7.
Trempolec N, Dave-Coll N, Nebreda AR. SnapShot: p38 MAPK substrates. Cell 2013; 152: 924.
Muniyappa H, Das KC. Activation of c-Jun N-Terminal Kinase (JNK) by widely used specific p38 MAPK inhibitor SB202190 and SB203580: A MLK-3 MKK7-dependent mechanism. Cell Signal 2008; 20(4): 675-83.
Ananieva O, Darragh J, Johansen C, et al. The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. Nat Immunol 2008; 9(9): 1028-36.
Mudgett JS, Ding J, Guh-Siesel L. Essential role for p38 α mitogen-activated protein kinase in placental angiogenesis. Proc Natl Acad Sci USA 2000; 97(19): 10454-9.
Charron CE, Russell P, Ito K, et al. RV568, a narrow spectrum kinase inhibitor with p38MAPK-α and -γ selectivity, supresses COPD inflammation. Eur Respir J 2017; 50(4): 1700188.
Gurgis FMS, Ziaziaris W, Munoz L. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: Role and targeting. Mol Pharmacol 2014; 85: 345-56.
Ronkina N, Kotlyarov A, Dittrich-Breiholz O, et al. The Mitogen-Activated Protein Kinase (MAPK)-activated protein kinases MK2 and MK3 cooperate in stimulation of tumor necrosis factor biosynthesis and stabilization of p38 MAPK. Mol Cell Biol 2007; 27: 170-81.
Herlaar E, Brown Z. p38 MAPK signalling cascades in inflammatory disease. Mol Med Today 1999; 5: 439-47.
Kumar S, Boehm J, Lee JC. p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; (2): 9-14.
Gorska MM, Liang Q, Stafford SJ, et al. MK2 controls the level of negative feedback in the NF-kB pathway and is essential for vascular permeability and airway inflammation. J Exp Med 2007; 204: 1637-52.
Moretto N, Bertolini S, Iadicicco C, et al. Cigarette smoke and its component acrolein augment IL-8/CXCL8 mRNA stability via p38 MAPK/MK2 signaling in human pulmonary cells. Am J Physiol Lung Cell Mol Physiol 2012; 303: L929-38.
Steele MP, Schwartz DA. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu Rev Med 2013; 64: 265-76.
Kage H, Borok Z. EMT and interstitial lung disease: A mysterious relationship. Curr Opin Pulm Med 2012; 18(5): 517-23.
Liu T, Warburton RR, Guevara OE, et al. Lack of MK2 Inhibits Myofibroblast Formation and Exacerbates Pulmonary Fibrosis. Am J Respir Cell Mol Biol 2007; 37: 507-17.
Sousa AM, Liu T, Guevara O, et al. Smooth muscle alpha-actin expression and myofibroblast differentiation by TGFbeta are dependent upon MK2. J Cell Biochem 2007; 100(6): 1581-92.
Cornell TT, Fleszar A, McHugh W, Blatt NB, Vine AML, Shanley TP. Mitogen-activated protein kinase phosphatase 2, MKP-2, regulates early inflammation in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2012; 303(3): L251-8.
Aggarwal NR, King LS, D’Alessio FR. Diverse macrophage populations mediate acute lung inflammation and resolution. Am J Physiol Lung Cell Mol Physiol 2014; 306(8): L709-25.
Cornell TT, Rodenhouse P, Cai Q, Sun L, Shanley TP. Mitogenactivated protein kinase phosphatase 2 regulates the inflammatory response in sepsis. Infect Immun 2010; 78(6): 2868-76.
Park MS, He Q, Edwards MG, et al. Mitogen-activated protein kinase phosphatase-1 modulates regional effects of injurious mechanical ventilation in rodent lungs. Am J Respir Crit Care Med 2012; 186(1): 72-81.
Erdem JS, Skaug V, Haugen A, Zienolddiny S. Loss of MKK3 and MK2 copy numbers in non-small cell lung cancer. J Cancer 2016; 7(5): 512-5.
Liu B, Yang L, Huang B, et al. A functional copy-number variation in MAPKAPK2 predicts risk and prognosis of lung cancer. Am J Hum Genet 2012; 91(2): 384-90.
Morandell S, Reinhardt HC, Cannell IG, et al. A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Reports 2013; 5(4): 868-77.
Johansen C, Funding AT, Otkjaer K, et al. Protein expression of TNFa in psoriatic skin is regulated at a post-transcriptional level by MAPKAPK-2. J Immunol 2006; 176: 1431-8.
Ray AL, Castillo EF, Morris KT, et al. Blockade of MK2 is protective in inflammation-associated colorectal cancer development. Int J Cancer 2016; 138: 770-5.
Oubrie A, Kaptein A. Zwart Ed, et al. Novel ATP competitive MK2 inhibitors with potent biochemical and cell-based activity throughout the series. Bioorg Med Chem Lett 2012; 22: 613-8.
Qin J, Dhondi P, Huang X, et al. Discovery of a potent dihydrooxadiazole series of non-ATP competitive MK2 (MAPKAPK2) inhibitors. ACS Med Chem Lett 2012; 3: 100-5.
Xiao D, Zhu X, Sofolarides M, et al. Discovery of a novel series of potent MK2 non-ATP competitive inhibitors usign 1,2-substituted azoles as cis-amide isosteres. Bioorg Med Chem Lett 2014; 24: 3609-13.
Schlapbach A, Huppertz C. Low molecular-weight MK2 inhibitors: A tough nut to crack! Future Med Chem 2009; 1: 1243-57.
Hillig RC, Eberspaecher U, Monteclaro F, et al. Structural basis for a high affinity inhibitor bound to protein kinase MK2. J Mol Biol 2007; 369: 735-45.
Mourey RJ, Burnette BL, Brustkern SJ, et al. A benzothiophene inhibitor of mitogen-activated protein kinase-activated protein kinase 2 inhibits tumor necrosis factor α production and has oral anti-inflammatory efficacy in acute and chronic models of inflammation. J Pharmacol Exp Ther 2010; 333: 797-807.
Swinney DC. Biochemical mechanisms of drug action: What does it take for success? Nat Rev Drug Discov 2004; 3: 801-8.
Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011; 10: 507-19.
Huang X, Zhu X, Chen X, et al. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors. Bioorg Med Chem Lett 2012; 22: 65-70.